hbvaxpro vaccine
merck sharp & dohme (new zealand) limited - hepatitis b vaccine, rdna 10 µg/ml - suspension for injection - 10 mcg/ml - active: hepatitis b vaccine, rdna 10 µg/ml excipient: aluminium as amorphous aluminum hydroxyphosphate sulphate borax formaldehyde potassium thiocyanate sodium chloride water for injection - immunisation against infection caused by all known subtypes of hepatitis b virus. hbvaxpro should also prevent hepatitis d (caused by the delta virus) since hepatitis d does not occur in the absence of hepatitis b infection.
hbvaxpro vaccine
merck sharp & dohme (new zealand) limited - hepatitis b vaccine, rdna 40 µg/ml - suspension for injection - 40 mcg/ml - active: hepatitis b vaccine, rdna 40 µg/ml excipient: aluminium as amorphous aluminum hydroxyphosphate sulphate borax formaldehyde potassium thiocyanate sodium chloride water for injection - immunisation against infection caused by all known subtypes of hepatitis b virus. hbvaxpro should also prevent hepatitis d (caused by the delta virus) since hepatitis d does not occur in the absence of hepatitis b infection.
vaqta 25 u 0.5 ml
merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - suspension for injection - hepatitis a virus antigen, inactivated 25 units / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in children and adolescents 12 months of age and older .
vaqta 50 uml
merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - suspension for injection - hepatitis a virus antigen, inactivated 50 u/ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 2 years of age and older.
crixivan
merck sharp & dohme (new zealand) limited - indinavir sulfate 250mg equivalent to 200 mg indinavir; ; - capsule - 200 mg - active: indinavir sulfate 250mg equivalent to 200 mg indinavir excipient: gelatin lactose magnesium stearate tekprint blue sb-6018 - indicated for the treatment of adults with hiv-1 infection. clinical studies demonstrated: · reduced risk of progression to an aids-defining illness or death · increased overall survival · durable reduction in serum viral rna · durable increase in cd4 cell counts
crixivan
merck sharp & dohme (new zealand) limited - indinavir sulfate 416.3mg equivalent to 333 mg indinavir; ; - capsule - 333 mg - active: indinavir sulfate 416.3mg equivalent to 333 mg indinavir excipient: gelatin lactose magnesium stearate
crixivan
merck sharp & dohme (new zealand) limited - indinavir sulfate 500mg equivalent to 400 mg indinavir; ; - capsule - 400 mg - active: indinavir sulfate 500mg equivalent to 400 mg indinavir excipient: gelatin lactose magnesium stearate tekprint green sb-4020 - indicated for the treatment of adults with hiv-1 infection. clinical studies demonstrated: · reduced risk of progression to an aids-defining illness or death · increased overall survival · durable reduction in serum viral rna · durable increase in cd4 cell counts
primaxin
merck sharp & dohme (new zealand) limited - cilastatin sodium 571mg equivalent to 500 mg cilastatin acid. (includes 4.6% overage).; imipenem monohydrate 560mg equivalent to 500 mg imipenem. (includes 4.6% overage).; - powder for infusion - 500mg/500mg - active: cilastatin sodium 571mg equivalent to 500 mg cilastatin acid. (includes 4.6% overage). imipenem monohydrate 560mg equivalent to 500 mg imipenem. (includes 4.6% overage). excipient: sodium bicarbonate
rotateq
merck sharp & dohme (new zealand) limited - rotavirus reassortant strain g1 2.2e+006 [iu] (nlt, at expiry); rotavirus reassortant strain g2 2.8e+006 [iu] (nlt, at expiry); rotavirus reassortant strain g3 2.2e+006 [iu] (nlt, at expiry); rotavirus reassortant strain g4 2e+006 [iu] (nlt, at expiry); rotavirus reassortant strain p1 2.3e+006 [iu] (nlt, at expiry) - oral solution - 2 ml - active: rotavirus reassortant strain g1 2.2e+006 [iu] (nlt, at expiry) rotavirus reassortant strain g2 2.8e+006 [iu] (nlt, at expiry) rotavirus reassortant strain g3 2.2e+006 [iu] (nlt, at expiry) rotavirus reassortant strain g4 2e+006 [iu] (nlt, at expiry) rotavirus reassortant strain p1 2.3e+006 [iu] (nlt, at expiry) excipient: rotavirus diluent & lpkm-3 (from actives) to approx 0.3 ml. includes animal materials as below. monobasic sodium phosphate monohydrate polysorbate 80 purified water sodium citrate dihydrate sodium hydroxide sucrose - rotateq is an oral pentavalent vaccine indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes g1, g2, g3, g4, and g-serotypes that contain p1a[8] (e.g., g9). rotateq may be administered as early as six weeks of age.
fosamax once weekly 70 mg tablets
merck sharp & dohme ireland (human health) limited - alendronate sodium - tablet - 70 milligram(s) - bisphosphonates; alendronic acid - bisphosphonate, for the treatment of bone diseases - it is indicated in adults for the treatment of postmenopausal osteoporosis. fosamax reduces the risk of vertebral and hip fractures.